Optimal treatment for ovarian cancer: Taxoids and beyond

Annals of Oncology

Volumn 11, Issue SUPPL. 3, 2000, Pages 131-139

  Vermorken, J B ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; GOLD 198; LIPOSOME; OXALIPLATIN; PACLITAXEL; PHOSPHORUS 32; PLATINUM DERIVATIVE; TOPOTECAN;

BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG INDUCED DISEASE; FEMALE; GYNECOLOGIC CANCER; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; NEUROTOXICITY; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 0033775348     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_3.131     Document Type: Conference Paper

References (52)

1. Ovarian cancer: Screening, treatment and follow-up
2. Advanced epithelial ovarian cancer: 1993 Consensus statements
3. Staging and surgical evaluation of ovarian cancer
4. Limited-stage ovarian carcinoma
5. Analysis of prognostic factors in 1287 patients with FIGO stage I invasive ovarian carcinoma
6. The accuracy of staging: An important prognostic determinator in stage I ovarian carcinoma. A multivariate analysis
7. Clinical trials in patients with epithelial ovarian cancer: Past, present and future
8. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Results of two prospective randomized trials
9. Watch and wait after careful surgical treatment and staging in well-differentiated early ovarian cancer
10. Randomized multicenter clinical trial in stage I epithelial ovarian cancer
11. Randomized trial comparing cisplatin with radioactive phosphorus or whole abdominal irradiation as adjuvant treatment of ovarian cancer
12. Adjuvant treatment for early epithelial ovarian cancer. Results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (P32)
13. Randomized clinical trial of adjuvant treatment of women with early (FIGO I-IIA high-risk) ovarian cancer - GOG 95
14. Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
15. Is stage I epithelial ovarian cancer overtreated both surgically and systemically? Results of a five-year cancer registry review
16. Ovarian cancer: Advances in genetic testing, prevention and treatment
17. Advanced epithelial ovarian cancer: 1998 Consensus statements
18. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
19. Randomized Intergroup Trial of cisplatin-paclitaxel vs cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer. Three-year results
20. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer
21. Randomized trial of paclitaxel (PTX) and carboplatin (CBDCA) vs a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin and cisplatin): The Third International Collaborative Ovarian Neoplasm Study (ICON-3)
22. Cyclophosphamide plus cisplatin vs cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma
23. Carboplatin versus cisplatin
24. Chemotherapy in advanced ovarian cancer: Four systematic meta-analyses from 37 individual trials
25. Paclitaxel-cisplatin vs paclitaxel-carboplatin in previously untreated ovarian cancer
26. Cisplatin/palcitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of AGO trial
27. Randomized phase III study of cisplatin-paclitaxel in optimal stage III epithelial ovarian cancer
28. A new standard of care for treatment of ovarian cancer
29. Optimum chemotherapy for ovarian cancer
30. Intraperitoneal vs intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: A randomized trial of the Gruppo Oncologico Nord-Ovest
31. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
32. Randomized phase III study of intravenous (iv) cisplatin/paclitaxel versus moderately high dose iv carboplatin followed by iv paclitaxel and intraperitoneal cisplatin in optimal residual ovarian cancer
33. The role of intraperitoneal chemotherapy in epithelial ovarian cancer
34. Dose-intensity in ovarian carcinoma. Hold, enough?
35. An updated analysis of a randomized study of single agent paclitaxel given weekly vs every 3 weeks to patients with ovarian cancer treated with prior platinum therapy
36. How long should first-line chemotherapy continue?
37. A randomised phase III trial of adjuvant intraperitoneal radioimmunotherapy in ovarian cancer
38. Maintenance treatment with interferon for advanced ovarian cancer
39. Intravenous chemotherapy for ovarian cancer - The state of the art?
40. Chemotherapy for ovarian cancer: Beyond paclitaxel plus carboplatin
41. New cytotoxics and non-cytotoxics in epithelial ovarian cancer
42. Phase I and pharmacologic study of the combination of paclitaxel, cisplatin and topotecan administered intravenously every 21 days as first-line chemotherapy in patients with advanced ovarian cancer
43. Phase I study of topotecan and cisplatin in patients with advanced solid tumors
44. Phase I trial and pharmacologic trial of sequences of paclitaxel and topotecan in previously treated epithelial ovarian malignancies. A Gynecologic Oncology Group Study
45. Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by palcitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: A National Cancer Institute of Canada Clinical Trials Group Study
46. Phase I-II sequential topotecan (TPT) chemotherapy in patients (pts) with small residual disease after taxol-carboplatin (TC) as first-line chemotherapy in advanced epithelial ovarian cancer (AEOC)
47. Gemcitabine (GEM) in combination with cisplatin (CP) in previously untreated patients > 60 years with FIGO stage III or iv epithelial ovarian cancer: A phase II study: Preliminary results
48. Gemcitabine combined with cisplatin first-line: A phase II study in patients with advanced epithelial ovarian cancer
49. Gemcitabine (GEMZAR) in combination with cisplatin (CP) in advanced ovarian cancer (AOC): A phase II study
50. Gemzar, Taxol, and Carboplatin in first-line treatment of ovarian cancer
51. The role of anthracyclines in epithelial ovarian cancer